Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Isopsoralen Improves Glucocorticoid-induced Osteoporosis by Regulating Purine Metabolism and Promoting cGMP/PKG Pathway-mediated Osteoblast Differentiation

Author(s): Defeng Liu, Lingyun Ma, Jihui Zheng, Zhenqun Zhang, Nana Zhang, Zhongqian Han, Xuejie Wang, Jianyong Zhao*, Shuquan Lv* and Huantian Cui*

Volume 25, Issue 4, 2024

Published on: 12 July, 2024

Page: [288 - 297] Pages: 10

DOI: 10.2174/0113892002308141240628071541

Price: $65

Abstract

Background: The effects of Isopsoralen (ISO) in promoting osteoblast differentiation and inhibiting osteoclast formation are well-established, but the mechanism underlying ISO's improvement of Glucocorticoid- Induced Osteoporosis (GIOP) by regulating metabolism remains unclear.

Methods: This study aims to elucidate the mechanism of ISO treatment for GIOP through non-targeted metabolomics based on ISO's efficacy in GIOP. Initially, we established a GIOP female mouse model and assessed ISO's therapeutic effects using micro-CT detection, biomechanical testing, serum calcium (Ca), and phosphorus (P) level detection, along with histological analyses using hematoxylin and eosin (HE), Masson, and tartrate-resistant acidic phosphatase (TRAP) staining. Subsequently, non-targeted metabolomics was employed to investigate ISO's impact on serum metabolites in GIOP mice. RT-qPCR and Western blot analyses were conducted to measure the levels of enzymes associated with these metabolites. Building on the metabolomic results, we explored the effects of ISO on the cyclic Guanosine Monophosphate (cGMP)/Protein Kinase G (PKG) pathway and its role in mediating osteoblast differentiation.

Results: Our findings demonstrate that ISO intervention effectively enhances the bone microarchitecture and strength of GIOP mice. It mitigates pathological damage, such as structural damage in bone trabeculae, reduced collagen fibers, and increased osteoclasts, while improving serum Ca and P levels in GIOP mice. Non-- targeted metabolomics revealed purine metabolism as a common pathway between the Control and GIOP groups, as well as between the ISO high-dose (ISOH) group and the GIOP group. ISO intervention upregulated inosine and adenosine levels, downregulated guanosine monophosphate levels, increased Adenosine Deaminase (ADA) expression, and decreased cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5) expression. Additionally, ISO intervention elevated serum cGMP levels, upregulated PKGI and PKGII expression in bone tissues, as well as the expression of Runt-related transcription factor 2 (Runx2) and Osterix, and increased serum Alkaline Phosphatase (ALP) activity.

Conclusion: In summary, ISO was able to enhance the bone microstructure and bone strength of GIOP mice and improve their Ca, P, and ALP levels, which may be related to ISO's regulation of purine metabolism and promotion of osteoblast differentiation mediated by the cGMP/PKG pathway. This suggests that ISO is a potential drug for treating GIOP. However, further research is still needed to explore the specific targets and clinical applications of ISO.

« Previous
[1]
Compston J. Glucocorticoid-induced osteoporosis: An update. Endocrine 2018; 61(1): 7-16.
[http://dx.doi.org/10.1007/s12020-018-1588-2] [PMID: 29691807]
[2]
Lane NE. Glucocorticoid-induced osteoporosis: New insights into the pathophysiology and treatments. Curr Osteoporos Rep 2019; 17(1): 1-7.
[http://dx.doi.org/10.1007/s11914-019-00498-x] [PMID: 30685820]
[3]
Hu K, Adachi JD. Glucocorticoid induced osteoporosis. Expert Rev Endocrinol Metab 2019; 14(4): 259-66.
[http://dx.doi.org/10.1080/17446651.2019.1617131] [PMID: 31094232]
[4]
Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: A systematic review and meta-analysis. Drug Des Devel Ther 2019; 13: 2843-52.
[http://dx.doi.org/10.2147/DDDT.S148654] [PMID: 31616133]
[5]
Li B, Wang Y, Gong S, et al. Puerarin improves OVX-induced osteoporosis by regulating phospholipid metabolism and biosynthesis of unsaturated fatty acids based on serum metabolomics. Phytomedicine 2022; 102: 154198.
[http://dx.doi.org/10.1016/j.phymed.2022.154198] [PMID: 35636175]
[6]
Si Z, Zhou S, Shen Z, Luan F. High-throughput metabolomics discovers metabolic biomarkers and pathways to evaluating the efficacy and exploring potential mechanisms of osthole against osteoporosis based on UPLC/Q-TOF-MS coupled with multivariate data analysis. Front Pharmacol 2020; 11: 741.
[http://dx.doi.org/10.3389/fphar.2020.00741] [PMID: 32670052]
[7]
Xu Y, Chen S, Yu T, Qiao J, Sun G. High-throughput metabolomics investigates anti-osteoporosis activity of oleanolic acid via regulating metabolic networks using ultra-performance liquid chromatography coupled with mass spectrometry. Phytomedicine 2018; 51: 68-76.
[http://dx.doi.org/10.1016/j.phymed.2018.09.235] [PMID: 30466629]
[8]
Wang T, Wang Y, Zhuang X, Luan F, Zhao C, Cordeiro MNDS. Interaction of coumarin phytoestrogens with ERα and ERβ: A molecular dynamics simulation study. Molecules 2020; 25(5): 1165.
[http://dx.doi.org/10.3390/molecules25051165] [PMID: 32150902]
[9]
Li YP, Wu B, Liang J, Li F. Isopsoralen ameliorates H2O2-induced damage in osteoblasts via activating the Wnt/β-catenin pathway. Exp Ther Med 2019; 18(3): 1899-906.
[http://dx.doi.org/10.3892/etm.2019.7741] [PMID: 31410152]
[10]
Wang J, Li SF, Wang T, et al. Isopsoralen-mediated suppression of bone marrow adiposity and attenuation of the adipogenic commitment of bone marrow-derived mesenchymal stem cells. Int J Mol Med 2017; 39(3): 527-38.
[http://dx.doi.org/10.3892/ijmm.2017.2880] [PMID: 28204811]
[11]
Yang Z, Huang J, Liu S, et al. The osteoprotective effect of psoralen in ovariectomy-induced osteoporotic rats via stimulating the osteoblastic differentiation from bone mesenchymal stem cells. Menopause 2012; 19(10): 1040-8.
[http://dx.doi.org/10.1097/gme.0b013e3182507e18] [PMID: 22781784]
[12]
Zhou Q, Guan Z, Liu S, et al. The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice. Aging 2022; 14(1): 272-85.
[http://dx.doi.org/10.18632/aging.203729] [PMID: 35027504]
[13]
Li H, Wang Y, Wang Y, et al. Mechanical study of alisol B 23-acetate on methionine and choline deficient diet-induced nonalcoholic steatohepatitis based on untargeted metabolomics. Biomed Chromatogr 2024; 38(1): e5763.
[http://dx.doi.org/10.1002/bmc.5763] [PMID: 37858975]
[14]
Pfeifer A, Kilić A, Hoffmann LS. Regulation of metabolism by cGMP. Pharmacol Ther 2013; 140(1): 81-91.
[http://dx.doi.org/10.1016/j.pharmthera.2013.06.001] [PMID: 23756133]
[15]
Shen YW, Cheng YA, Li Y, Li Z, Yang BY, Li X. Sambucus williamsii Hance maintains bone homeostasis in hyperglycemia-induced osteopenia by reversing oxidative stress via cGMP/PKG signal transduction. Phytomedicine 2023; 110: 154607.
[http://dx.doi.org/10.1016/j.phymed.2022.154607] [PMID: 36610352]
[16]
Jha SS. Glucocorticoid-Induced Osteoporosis (GIOP). Indian J Orthop 2023; 57(S1) (Suppl. 1): 181-91.
[http://dx.doi.org/10.1007/s43465-023-01037-8] [PMID: 38107807]
[17]
Chopra B, Dhingra AK, Dhar KL. Psoralea corylifolia L. (Buguchi) — Folklore to modern evidence: Review. Fitoterapia 2013; 90: 44-56.
[http://dx.doi.org/10.1016/j.fitote.2013.06.016] [PMID: 23831482]
[18]
Chatterjee M, Faot F, Correa C, Kerckhofs J, Vandamme K. Is the jaw bone micro-structure altered in response to osteoporosis and bisphosphonate treatment? A Micro-CT analysis. Int J Mol Sci 2021; 22(12): 6559.
[http://dx.doi.org/10.3390/ijms22126559] [PMID: 34207275]
[19]
Chen M, Fu W, Xu H, Liu C. Pathogenic mechanisms of glucocorticoid-induced osteoporosis. Cytokine Growth Factor Rev 2023; 70: 54-66.
[http://dx.doi.org/10.1016/j.cytogfr.2023.03.002] [PMID: 36906448]
[20]
Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: Review of a novel, easy to swallow formulation. Clin Interv Aging 2013; 8: 681-8.
[http://dx.doi.org/10.2147/CIA.S37199] [PMID: 23766643]
[21]
Wang L, Zhang HY, Gao B, et al. Tetramethylpyrazine protects against glucocorticoid-induced apoptosis by promoting autophagy in mesenchymal stem cells and improves bone mass in glucocorticoid-induced osteoporosis rats. Stem Cells Dev 2017; 26(6): 419-30.
[http://dx.doi.org/10.1089/scd.2016.0233] [PMID: 27917698]
[22]
Chen Z, Xue J, Shen T, Ba G, Yu D, Fu Q. Curcumin alleviates glucocorticoid-induced osteoporosis by protecting osteoblasts from apoptosis in vivo and in vitro. Clin Exp Pharmacol Physiol 2016; 43(2): 268-76.
[http://dx.doi.org/10.1111/1440-1681.12513] [PMID: 26515751]
[23]
Tolba MF, El-Serafi AT, Omar HA. Caffeic acid phenethyl ester protects against glucocorticoid-induced osteoporosis in vivo: Impact on oxidative stress and RANKL/OPG signals. Toxicol Appl Pharmacol 2017; 324: 26-35.
[http://dx.doi.org/10.1016/j.taap.2017.03.021] [PMID: 28363435]
[24]
Lu H, Yan HW. Long-term effect of cervus and cucumis polypeptide combined with zoledronic acid in treating glucocorticoids-induced osteoporosis and the effect on bone mineral density. Chinese Gen Prac 2017; 20(S1): 224-6.
[25]
Ling C, Miao Z, Xiao M, et al. The association of gut microbiota with osteoporosis is mediated by amino acid metabolism: Multiomics in a large cohort. J Clin Endocrinol Metab 2021; 106(10): e3852-64.
[http://dx.doi.org/10.1210/clinem/dgab492] [PMID: 34214160]
[26]
Miyamoto K, Hirayama A, Sato Y, et al. A metabolomic profile predictive of new osteoporosis or sarcopenia development. Metabolites 2021; 11(5): 278.
[http://dx.doi.org/10.3390/metabo11050278] [PMID: 33924750]
[27]
Lu X, Chen Y, Wang H, et al. Integrated lipidomics and transcriptomics characterization upon aging-related changes of lipid species and pathways in human bone marrow mesenchymal stem cells. J Proteome Res 2019; 18(5): 2065-77.
[http://dx.doi.org/10.1021/acs.jproteome.8b00936] [PMID: 30827117]
[28]
Qian C, Wang Q, Qiao Y, et al. Arachidonic acid in aging: New roles for old players. J Adv Res 2024; S2090-1232(24)00180-2.
[http://dx.doi.org/10.1016/j.jare.2024.05.003] [PMID: 38710468]
[29]
Liang WD, Huang PJ, Xiong LH, et al. Metabolomics and its application in the mechanism analysis on diabetic bone metabolic abnormality. Eur Rev Med Pharmacol Sci 2020; 24(18): 9591-600.
[PMID: 33015802]
[30]
Zhang X, Xu H, Li GHY, et al. Metabolomics insights into osteoporosis through association with bone mineral density. J Bone Miner Res 2020; 36(4): 729-38.
[http://dx.doi.org/10.1002/jbmr.4240] [PMID: 33434288]
[31]
Yang K, Li J, Tao L. Purine metabolism in the development of osteoporosis. Biomed Pharmacother 2022; 155: 113784.
[http://dx.doi.org/10.1016/j.biopha.2022.113784] [PMID: 36271563]
[32]
Kazemzadeh-Narbat M, Annabi N, Tamayol A, Oklu R, Ghanem A, Khademhosseini A. Adenosine-associated delivery systems. J Drug Target 2015; 23(7-8): 580-96.
[http://dx.doi.org/10.3109/1061186X.2015.1058803] [PMID: 26453156]
[33]
Alabed S, Sabouni A, Providencia R, Atallah E, Qintar M, Chico TJA. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Cochrane Libr 2017; 2017(10): CD005154.
[http://dx.doi.org/10.1002/14651858.CD005154.pub4] [PMID: 29025197]
[34]
Atif M, Alsrhani A, Naz F, et al. Targeting adenosine receptors in neurological diseases. Cell Reprogram 2021; 23(2): 57-72.
[http://dx.doi.org/10.1089/cell.2020.0087] [PMID: 33861641]
[35]
Da W, Tao L, Zhu Y. The role of osteoclast energy metabolism in the occurrence and development of osteoporosis. Front Endocrinol 2021; 12: 675385.
[http://dx.doi.org/10.3389/fendo.2021.675385] [PMID: 34054735]
[36]
Newman H, Varghese S. Extracellular adenosine signaling in bone health and disease. Curr Opin Pharmacol 2023; 70: 102378.
[http://dx.doi.org/10.1016/j.coph.2023.102378] [PMID: 37044008]
[37]
Kaster MP, Budni J, Gazal M, Cunha MP, Santos ARS, Rodrigues ALS. The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A2A receptors. Purinergic Signal 2013; 9(3): 481-6.
[http://dx.doi.org/10.1007/s11302-013-9361-8] [PMID: 23613131]
[38]
Dewulf JP, Marie S, Nassogne MC. Disorders of purine biosynthesis metabolism. Mol Genet Metab 2022; 136(3): 190-8.
[http://dx.doi.org/10.1016/j.ymgme.2021.12.016] [PMID: 34998670]
[39]
Schall N, Garcia JJ, Kalyanaraman H, et al. Protein kinase G1 regulates bone regeneration and rescues diabetic fracture healing. JCI Insight 2020; 5(9): e135355.
[http://dx.doi.org/10.1172/jci.insight.135355] [PMID: 32315291]
[40]
Kim SM, Yuen T, Iqbal J, Rubin MR, Zaidi M. The NO–cGMP–PKG pathway in skeletal remodeling. Ann N Y Acad Sci 2021; 1487(1): 21-30.
[http://dx.doi.org/10.1111/nyas.14486] [PMID: 32860248]
[41]
Miyazawa T, Ogawa Y, Chusho H, et al. Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology 2002; 143(9): 3604-10.
[http://dx.doi.org/10.1210/en.2002-220307] [PMID: 12193576]
[42]
Shrivats AR, Hsu E, Averick S, et al. Cationic Nanogel-mediated Runx2 and Osterix siRNA Delivery Decreases Mineralization in MC3T3 Cells. Clin Orthop Relat Res 2015; 473(6): 2139-49.
[http://dx.doi.org/10.1007/s11999-014-4073-0] [PMID: 25448327]
[43]
Ma WW, Huang W-Z, Li L-D, et al. Study on the mechanism of Guilu Erxian gum in the treatment of osteoporosis based on network pharmacology and cell experiment. Trad Med Res 2023; 8(12): 69.
[http://dx.doi.org/10.53388/TMR20230704002]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy